$ELOX
Eloxx Pharmaceuticals, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021025356 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.340M $5.220M
YoY Change -16.86% -12.42%
% of Gross Profit
Research & Development $4.070M $4.767M
YoY Change -14.62% -20.8%
% of Gross Profit
Depreciation & Amortization $16.00K $19.00K
YoY Change -15.79% -36.67%
% of Gross Profit
Operating Expenses $8.414M $13.77M
YoY Change -38.88% 14.95%
Operating Profit -$8.414M -$13.77M
YoY Change -38.88% 14.95%
Interest Expense -$280.0K -$180.0K
YoY Change 55.56%
% of Operating Profit
Other Income/Expense, Net -$280.0K -$179.0K
YoY Change 56.42% -398.33%
Pretax Income -$8.690M -$13.95M
YoY Change -37.71% 17.03%
Income Tax
% Of Pretax Income
Net Earnings -$8.694M -$13.95M
YoY Change -37.66% 17.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$216.3K -$348.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.25M $43.96M
YoY Change -58.48% -17.84%
Cash & Equivalents $18.25M $25.88M
Short-Term Investments $18.08M
Other Short-Term Assets $1.710M $1.970M
YoY Change -13.2% 0.51%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.96M $45.93M
YoY Change -56.54% -17.19%
LONG-TERM ASSETS
Property, Plant & Equipment $117.0K $182.0K
YoY Change -35.71% -86.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $110.0K
YoY Change 17.02%
Total Long-Term Assets $410.0K $1.114M
YoY Change -63.2% -22.15%
TOTAL ASSETS
Total Short-Term Assets $19.96M $45.93M
Total Long-Term Assets $410.0K $1.114M
Total Assets $20.37M $47.04M
YoY Change -56.7% -17.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $490.0K $1.389M
YoY Change -64.72% -37.99%
Accrued Expenses $2.917M $3.568M
YoY Change -18.25% -22.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.562M $4.772M
YoY Change 16.55% 384.96%
Total Short-Term Liabilities $12.69M $11.08M
YoY Change 14.49% 31.64%
LONG-TERM LIABILITIES
Long-Term Debt $4.913M $9.385M
YoY Change -47.65% -30.01%
Other Long-Term Liabilities $10.00K $320.0K
YoY Change -96.88% -49.21%
Total Long-Term Liabilities $4.913M $9.385M
YoY Change -47.65% -30.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.69M $11.08M
Total Long-Term Liabilities $4.913M $9.385M
Total Liabilities $17.62M $20.78M
YoY Change -15.22% -7.46%
SHAREHOLDERS EQUITY
Retained Earnings -$180.3M -$151.0M
YoY Change 19.43% 53.95%
Common Stock $404.0K $179.0M
YoY Change -99.77% 34.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.750M $26.26M
YoY Change
Total Liabilities & Shareholders Equity $20.37M $47.04M
YoY Change -56.7% -17.31%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$8.694M -$13.95M
YoY Change -37.66% 17.03%
Depreciation, Depletion And Amortization $16.00K $19.00K
YoY Change -15.79% -36.67%
Cash From Operating Activities -$7.685M -$11.92M
YoY Change -35.55% 29.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $15.79M
YoY Change -100.0%
Cash From Investing Activities $0.00 $15.79M
YoY Change -100.0% -276.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.262M -483.0K
YoY Change -361.28% -109.32%
NET CHANGE
Cash From Operating Activities -7.685M -11.92M
Cash From Investing Activities 0.000 15.79M
Cash From Financing Activities 1.262M -483.0K
Net Change In Cash -6.423M 3.382M
YoY Change -289.92% -137.82%
FREE CASH FLOW
Cash From Operating Activities -$7.685M -$11.92M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
404000
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1828000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
183250000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4767000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4767000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y14D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M26D
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40157187
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
404000
CY2020Q1 elox Restructuring Charges Includes Stock Based Compensation
RestructuringChargesIncludesStockBasedCompensation
3994000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
8414000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
13767000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8414000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13767000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-280000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-179000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-13946000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40180131
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40074275
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-13946000
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
47000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8694000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13899000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8694000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-13946000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1308000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3995000
CY2021Q1 us-gaap Depreciation
Depreciation
16000
CY2020Q1 us-gaap Depreciation
Depreciation
19000
CY2021Q1 elox Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
132000
CY2020Q1 elox Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
102000
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
110000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
152000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
460000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
573000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-482000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1087000
CY2021Q1 elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-132000
CY2020Q1 elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-102000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7685000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11924000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15750000
CY2020Q1 us-gaap Payments For Proceeds From Longterm Investments
PaymentsForProceedsFromLongtermInvestments
-39000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15789000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1250000
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
833000
CY2021Q1 elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
2606000
CY2020Q1 elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
402000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
116000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1262000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-483000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6423000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3382000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24724000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22536000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18301000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25918000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18247000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25875000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
54000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
43000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
144000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
272000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10230000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
36213000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
47000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-13946000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180300000
CY2021Q1 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
18200000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5000000.0
CY2020Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
631000
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
297000
CY2021Q1 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
929000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
170000
CY2021Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
433000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
368000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1659000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1169000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
446000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
446000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
329000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
313000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
117000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133000
CY2021Q1 us-gaap Depreciation
Depreciation
16000
CY2020Q1 us-gaap Depreciation
Depreciation
19000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4148000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
5398000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
417000
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9963000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
388000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
9575000
CY2021Q1 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1065000
CY2020Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
802000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
688000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1315000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1062000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2021Q1 elox Accrued Interest On Debt
AccruedInterestOnDebt
53000
CY2020Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
57000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
49000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39000
CY2020Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
258000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2917000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2886000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1936183
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
677729
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.02
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4394283
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.28
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
841840
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2142864
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.66
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
764096
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5562000
CY2021Q1 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-900000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4913000
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
323892
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.31
CY2021Q1 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P2Y5M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3803061
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.16
CY2021Q1 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
3400000
CY2020Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
800000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
86507
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.56
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3995000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1308000
CY2021Q1 elox Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost
18200000
CY2021Q1 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
18200000
CY2020Q4 elox Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost
24700000
CY2020Q4 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
24700000
CY2021Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q1 elox Fair Value Assets Transfers Between Level2 And Level3 Description
FairValueAssetsTransfersBetweenLevel2AndLevel3Description
the Company did not have any transfers of financial assets between levels
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
2000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-280000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-179000
CY2021Q1 us-gaap Interest Expense Other
InterestExpenseOther
260000
CY2020Q1 us-gaap Interest Expense Other
InterestExpenseOther
412000
CY2020Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
245000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-20000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8694000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-13946000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40180131
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40074275
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2020Q4 us-gaap Restructuring Reserve
RestructuringReserve
258000
CY2021Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
258000
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
1870000
CY2020Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
544000
CY2020Q1 us-gaap Restructuring Reserve
RestructuringReserve
1326000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4986331
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5592890
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
13
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
4000000.0
CY2020Q1 elox Restructuring And Related Cost Stock Based Compensation Expense
RestructuringAndRelatedCostStockBasedCompensationExpense
2100000
CY2020Q1 elox Restructuring And Related Costs Severance Cost Payment Period
RestructuringAndRelatedCostsSeveranceCostPaymentPeriod
P1Y

Files In Submission

Name View Source Status
0001564590-21-025356-index-headers.html Edgar Link pending
0001564590-21-025356-index.html Edgar Link pending
0001564590-21-025356.txt Edgar Link pending
0001564590-21-025356-xbrl.zip Edgar Link pending
elox-10q_20210331.htm Edgar Link pending
elox-10q_20210331_htm.xml Edgar Link completed
elox-20210331.xsd Edgar Link pending
elox-20210331_cal.xml Edgar Link unprocessable
elox-20210331_def.xml Edgar Link unprocessable
elox-20210331_lab.xml Edgar Link unprocessable
elox-20210331_pre.xml Edgar Link unprocessable
elox-ex101_13.htm Edgar Link pending
elox-ex104_51.htm Edgar Link pending
elox-ex105_50.htm Edgar Link pending
elox-ex311_8.htm Edgar Link pending
elox-ex312_7.htm Edgar Link pending
elox-ex321_6.htm Edgar Link pending
elox-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ggq4yuveq1u3000001.jpg Edgar Link pending
ggq4yuveq1u3000030.jpg Edgar Link pending
ggq4yuveq1u3000031.jpg Edgar Link pending
ggq4yuveq1u3000033.jpg Edgar Link pending
ggq4yuveq1u3000041.jpg Edgar Link pending
ggq4yuveq1u3000043.jpg Edgar Link pending
ggq4yuveq1u3000049.jpg Edgar Link pending
gpmagwdxl5go000001.jpg Edgar Link pending
gpmagwdxl5go000006.jpg Edgar Link pending
gpmagwdxl5go000009.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending